Phase 1Completed
Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)
A Phase 1, Randomized, Open-Label Study to Evaluate the Effect of Cyclosporine on the Plasma Pharmacokinetics of AT-527 in Healthy Adult Male Subjects
- Sponsor
- Atea Pharmaceuticals, Inc. (Industry)
- Enrollment
- 24 enrolled
- Conditions
- Healthy Volunteer Study
- Interventions
- AT-527 550 mg + cyclosporine; AT-527 550 mg + cyclosporine
- Ages
- adults, older adults
- Registry
- NCT04849299
Full record on ClinicalTrials.gov
From the registry
This study will determine the effect of cyclosporine on the PK of AT-527 (R07496998) in healthy male subjects
Primary outcomes
- Pharmacokinetics (PK) of AT-527 (R07496998): Cmax
- Pharmacokinetics (PK) of AT-527 (R07496998): AUC
History
Last registry update
Primary completion
Registered
Started